UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
$161.88
arrow_upward
+0.63%(+1.01) 1D
Nov 6, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
$158.52
High
$162.97
Low
$158.52
Mkt. cap
56.58B
Avg. vol.
46.92K
Volume
21.23K
52-wk high
$168.76
52-wk low
$110.55
Beta
0.51
Shares outstanding
389.01M
No. of employees
9K
Open
$158.52
High
$162.97
Low
$158.52
Mkt. cap
56.58B
Avg. vol.
46.92K
Volume
21.23K
52-wk high
$168.76
52-wk low
$110.55
Beta
0.51
Shares outstanding
389.01M
No. of employees
9K
News stories
From web sources and news partners
marketscreener.com
·
1 hour ago
S&P 500 index pulled back after the Stockholm Stock Exchange closed on Friday
BigGo Finance
·
3 hours ago
Goldman Sachs Panic Index Breaches Extreme 9.5 Threshold; History Shows S&P 500 Averaged 4.6% Gain Over Following Three Months
JournalArta
·
1 hour ago
Tech Stocks Now Cheaper Than S&P 500 for First Time Since 2017
The Motley Fool
·
13 hours ago
No Matter What Happens to the S&P 500 in November, These 3 Dividend Stocks Belong in Your Portfolio
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
CEOJean-Christophe Tellier
Employees9K
FoundedJan 18, 1928
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteucb.com